• In August 2026, Krystal Biotech reported second-quarter 2026 results showing net income of US$54.77 million, up from US$38.33 million a year earlier, with basic earnings per share from continuing operations rising to US$1.85 and diluted earnings per share to US$1.79.
• Over the first six months of 2026, net income reached US$110.70 million and basic earnings per share from continuing operations climbed to US$3.76, highlighting a meaningful increase in profitability compared with the prior-year period.
• Next, we’ll examine how this stronger net income performance might influence Krystal Biotech’s existing investment narrative around growth, concentration risk, and profitability.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Krystal Biotech Investment Narrative Recap

To own Krystal Biotech, you need to believe VYJUVEK can sustain meaningful demand while the broader gene therapy pipeline matures into additional profit sources. The latest Q2 2026 net income of US$54.77 million, contributing to US$110.70 million over six months, reinforces the profitability side of that thesis. It does not, however, remove the near term concentration risk around VYJUVEK or the earnings volatility that can come from variable treatment patterns and reimbursement outcomes.

Among recent announcements, the May 2026 UK marketing authorization for VYJUVEK stands out alongside these earnings. Together, they underline how international approvals, once supported by reimbursement decisions, could gradually broaden the revenue base beyond the US. That opportunity sits against the same key risk: if European or Japanese pricing and access prove slower or less favorable than hoped, Krystal’s growing profit stream could remain heavily tied to a single product for longer than investors might like.

Yet behind the rising profits, investors should be aware that VYJUVEK’s revenue still depends on...

Krystal Biotech's narrative projects $1.0 billion revenue and $552.3 million earnings by 2029.

Uncover how Krystal Biotech's forecasts yield a $361.67 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Before this earnings beat, some of the most optimistic analysts were already modeling about US$1.4 billion in 2029 revenue and US$947.2 million in earnings, while also warning that any slowdown in pipeline progress could leave you exposed to a far more concentrated, and potentially bumpier, profit story over time.

Explore 5 other fair value estimates on Krystal Biotech - why the stock might be worth 13% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Krystal Biotech research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Krystal Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Krystal Biotech's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.